Newsletter Subject

Editor's pick: Our most important health stories of 2023

From

smartbrief.com

Email Address

livescience@smartbrief.com

Sent On

Tue, Dec 26, 2023 04:19 PM

Email Preheader Text

Our biggest health stories of 2023 | New Alzheimer's drug slightly slows cognitive decline. Experts

Our biggest health stories of 2023 | New Alzheimer's drug slightly slows cognitive decline. Experts say it's not a silver bullet. | World's 1st CRISPR therapy approved. Here's how it works. Created for {EMAIL} | [Web Version]( December 26, 2023 CONNECT WITH LIVESCIENCE  [Facebook]( [X](  [LIVESCIENCE]( Amazing science every day [SIGN UP]( ⋅ [WEBSITE](  [] Top Science News [] Our biggest health stories of 2023 Health channel editor Nicoletta Lanese looks back on some of our standout health stories from the past year. This year brought the the approval of medicines that could be paradigm-shifting: January [brought a new drug for Alzheimer's]( that's only the second of its kind, May saw the [first-ever gene therapy]( for a rare, debilitating skin-blister disorder, and as of June, psychedelics can now be used as [psychiatric treatments in Australia](. (With trials ongoing in the U.S., we could be close behind on that last one.) But arguably, the most formative development we witnessed in medicine this year was the approval of the [world's first therapy built upon the gene-editing tool CRISPR](. It's been only 11 years since CRISPR was launched to fame as a gene-editing system, thanks to a seminal 2012 paper. It's remarkable that scientists have been able to rapidly co-opt the microbial defense system as useful medicine. And from its advent, CRISPR was predicted to be a potential game-changer for conditions like sickle-cell disease (meaning conditions that have a discrete, well-defined genetic cause) and it's encouraging to see that prediction now come true. And there will be more CRISPR news coming in 2024, as additional therapies for [everything from HIV to high cholesterol]( move through trials. I think we'll someday look back on the approval of the first CRISPR therapy in terms of "before and after," it may well mark the start of a new era in medicine, one that comes with ethical quandaries we haven't fully tackled yet. [] [New Alzheimer's drug slightly slows cognitive decline. Experts say it's not a silver bullet.]( (selvanegra via Getty Images) [New Alzheimer's drug slightly slows cognitive decline. Experts say it's not a silver bullet.]( Experts weigh in on whether the newly approved Alzheimer's treatment lecanemab is worth taking. [Read More]( [] - [World's 1st CRISPR therapy approved. Here's how it works.]( U.K. regulators have approved the use of a CRISPR therapy called Casgevy to treat two inherited blood disorders. But what is it and how does it work? [] - [Australia clears legal use of MDMA and psilocybin to treat PTSD and depression]( Starting July 1, 2023, Australia will allow psychiatrists to prescribe certain hallucinogens in medical settings to treat PTSD and treatment-resistant depression. [] - [New gene therapy gel is the 1st approved treatment for rare and painful 'butterfly disease']( A new gene therapy gel is the first-ever approved treatment for the most severe forms of "butterfly disease," a rare and painful skin blistering condition. [] [REPROGRAMMING INFLAMMATION]( (Nicholas Forder) [REPROGRAMMING INFLAMMATION]( Our health reporter Emily Cooke wrote about one of our bodies' superheros that can sometimes become a villain: inflammation. Scientists are working to reign in chronic inflammation in the bodya, rather than switching it all the way off, which would hobble the immune system, they're developing strategies to simply turn down the dial. Is there a way to turn harmful, ongoing inflammation back into a helpful, transient defense strategy? [Read More]( [] [RETIRING ANTIBIOTICS]( (TUMEGGY/SCIENCE PHOTO LIBRARY via Getty Images) [RETIRING ANTIBIOTICS]( I wrote about [up-and-coming medicines that could replace antibiotics](, which are growing less effective by the year. The spread of antibiotic resistance represents a major threat to humanity, making common infections harder to cure. We need to find drugs that are invulnerable to drug resistance, so scientists are looking to tiny, protein sabers; precisely engineered molecules; bacteria-killing viruses; and CRISPR. [Read More]( [] HONORABLE MENTIONS The global effort to end the AIDS epidemic by 2030 is [still going strong, but faces tall hurdles](. In the meantime, we've seen a few people join the short list of individuals [who have potentially]( [been cured of HIV](. In a big shift, the FDA [retired its rule that drugs must be tested]( in animals to be approved. Potential alternatives to animal testing, such as organoids, have [grown more sophisticated]( and some have [even been harnessed in computer systems](. And finally, 2023 brought us [the first draft of the human "pangenome"]( and [most detailed map of the human brain]( ever conceived, so even as drug development advances at a rapid pace, we're still learning about the fundamentals of what makes us human. [] As always, thanks for reading, and we'll see you in 2024! Cheers, Nicoletta Lanese Health Channel Editor nlanese@livescience.com   [Sign Up]( | [Update Profile]( | [Unsubscribe]( [Privacy Policy]( | [Cookies Policy]( | [Terms and Conditions]( CONTACT US: [FEEDBACK](mailto:livescience@smartbrief.com) | [ADVERTISE]( [Future]( Future US LLC © Full 7th Floor, 130 West 42nd Street, New York, NY, 10036

Marketing emails from smartbrief.com

View More
Sent On

06/12/2024

Sent On

05/12/2024

Sent On

04/12/2024

Sent On

03/12/2024

Sent On

03/12/2024

Sent On

02/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.